Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 10/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | NPY1R | P25929 | 1/20 | 0.40 |
| ▸ | NPY4R | P50391 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13815093 | 0.93 | AAK1 (0.43) | AAK1LMNAPOLBCHEK1NPY1R | |
| SCHEMBL10262675 | 0.92 | NPY4R (0.42) | AAK1LMNAMEN1KMT2ANPY1R | |
| SCHEMBL12444369 | 0.92 | NPY4R (0.42) | AAK1LMNAMEN1KMT2ANPY1R | |
| SCHEMBL16285905 | 0.92 | NPY4R (0.42) | AAK1LMNAMEN1KMT2ANPY1R | |
| SCHEMBL15138938 | 0.92 | NPY4R (0.42) | AAK1LMNAMEN1KMT2ANPY1R | |
| SCHEMBL19945118 | 0.90 | NPY4R (0.43) | AAK1LMNAMEN1KMT2ANPY1R | |
| SCHEMBL13973873 | 0.89 | LMNA (0.42) | LMNAMEN1KMT2APOLB | |
| SCHEMBL13973694 | 0.89 | NPY4R (0.41) | AAK1LMNAMEN1KMT2ANPY1R | |
| SCHEMBL10262721 | 0.89 | NPY4R (0.41) | AAK1LMNAMEN1KMT2ANPY1R | |
| SCHEMBL12515411 | 0.89 | NPY4R (0.41) | AAK1LMNAMEN1KMT2ANPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140051762-A1 | POLYCATIONIC COMPOUNDS AND USES THEREOF | POLYMEDIX, INC. | 2014-02-20 | — | — | US | disclosed |
| US-7553876-B2 | Polycationic compounds and uses thereof | POLYMEDIX, INC. (US) | 2009-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051762-A1 | POLYCATIONIC COMPOUNDS AND USES THEREOF | VEGFA, VHL, PGF | AAK1 3707/4885LMNA 3716/4885MEN1 1338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.